Optimal design methods that are robust to uncertainty

Assumptions are usually made when optimising design for an experiment. Unexpected departure from the assumptions may result in suboptimal design. This thesis aims to address the issue of optimal design under uncertainties. Various optimisation methods were proposed to locate optimal design that is efficient even if the assumptions do not fully hold. A hypercube optimal design (HClnD) was proposed to address the issue of uncertainty in the parameter space, where D-optimal design for nonlinear models has an issue of dependency on the parameter values. The HClnD criterion is presented in Chapter 2 and was compared to other robust design criteria in terms of efficiency, relative errors and computational cost with simulation studies. The performance of HClnD was further evaluated in Chapter 3 where the optimality criteria in this chapter are solved analytically whenever possible and numerically otherwise for two simple nonlinear models. HClnD was shown to be as efficient as other robust methods and consumed less computational cost. This robust criterion was applied prospectively to design a three arm double blind pharmacokinetic (PK) clinical study for two drugs (midazolam and droperidol). The design was evaluated in Chapter 4. An adaptive optimal design method was proposed in Chapter 5 to design experiments for PK bridging studies. In a PK bridging study the researcher uses knowledge of the PK model from a prior-population to design the experiment for a target-population. The design is suboptimal if the PK profile of prior and target-populations are widely diverged. The proposed adaptive optimal design was compared to optimal design for target-population based solely on the prior-population information. The proposed method was superior in the estimation precision when the PK profiles of the two populations are widely divergent and comparable precision when the PK profiles are similar. Sampling windows is used to ensure certain degree of design efficiency under execution uncertainty, where samples may not be collected following exactly the optimal design. Two methods to construct sampling windows for nonlinear mixed effects models were proposed in Chapter 6. Initially a naive adaptive method that determines the window for the next sample when the previous and current samples become available was proposed. Another method is a recursive random sampling method that is based on the Gibbs sampling techniques. Both methods were applied to locate sampling windows for a population PK study and tested via simulation. Finally, an optimal design method to minimise the cost for phase II PK clinical studies was proposed in Chapter 7. An additional level of uncertainty when designing phase II clinical study based on the population PK estimates from healthy volunteers in phase I study was incorporated in the form of hyperprior distribution. In this design, the expected cost is minimised. The resulted optimal design accounts for both cost of the study and the probability of study failure. The proposed optimisation method…

[1]  Leon Aarons,et al.  An Effective Approach for Obtaining Optimal Sampling Windows for Population Pharmacokinetic Experiments , 2008, Journal of biopharmaceutical statistics.

[2]  C. Schermer,et al.  Methamphetamine use in trauma patients: a population-based study. , 1999, Journal of the American College of Surgeons.

[3]  Christopher J. Nachtsheim,et al.  Model Robust, Linear-Optimal Designs , 1982 .

[4]  James Miner,et al.  Management of acute undifferentiated agitation in the emergency department: a randomized double-blind trial of droperidol, ziprasidone, and midazolam. , 2005, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.

[5]  W K Wong,et al.  Optimal treatment allocation in comparative biomedical studies. , 2000, Statistics in medicine.

[6]  P Heizmann,et al.  Pharmacokinetics and bioavailability of midazolam in man. , 1983, British journal of clinical pharmacology.

[7]  S B Duffull,et al.  Optimal Design Criteria for Discrimination and Estimation in Nonlinear Models , 2009, Journal of biopharmaceutical statistics.

[8]  Donald Geman,et al.  Stochastic Relaxation, Gibbs Distributions, and the Bayesian Restoration of Images , 1984, IEEE Transactions on Pattern Analysis and Machine Intelligence.

[9]  L. White An extension of the General Equivalence Theorem to nonlinear models , 1973 .

[10]  Vladimir Dragalin,et al.  Implementation of an adaptive group sequential design in a bioequivalence study. , 2007, Pharmaceutical statistics.

[11]  Stephen B. Duffull,et al.  The use of simulated annealing for finding optimal population designs , 2002, Comput. Methods Programs Biomed..

[12]  Stephen B. Duffull,et al.  Optimal Design for Model Discrimination and Parameter Estimation for Itraconazole Population Pharmacokinetics in Cystic Fibrosis Patients , 2005, Journal of Pharmacokinetics and Pharmacodynamics.

[13]  W. G. Hunter,et al.  The use of prior distributions in the design of experiments for parameter estimation in non-linear situations: multiresponse case. , 1967, Biometrika.

[14]  S. Duffull,et al.  Estimating risk from underpowered, but statistically significant, studies: was APPROVe on TARGET? , 2011, Journal of clinical pharmacy and therapeutics.

[15]  E. Läuter,et al.  Optimal multipurpose designs for regression models , 1976 .

[16]  P. Mykland,et al.  Nonlinear Experiments: Optimal Design and Inference Based on Likelihood , 1993 .

[17]  Stephen Duffull,et al.  Methods of Robust Design of Nonlinear Models with an Application to Pharmacokinetics , 2010, Journal of biopharmaceutical statistics.

[18]  K. Smith ON THE STANDARD DEVIATIONS OF ADJUSTED AND INTERPOLATED VALUES OF AN OBSERVED POLYNOMIAL FUNCTION AND ITS CONSTANTS AND THE GUIDANCE THEY GIVE TOWARDS A PROPER CHOICE OF THE DISTRIBUTION OF OBSERVATIONS , 1918 .

[19]  Shein-Chung Chow,et al.  BRIDGING STUDIES IN CLINICAL DEVELOPMENT , 2002, Journal of biopharmaceutical statistics.

[20]  Mats O. Karlsson,et al.  Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies , 2007, Journal of Pharmacokinetics and Pharmacodynamics.

[21]  Leon Aarons,et al.  Bayesian Optimal Designs for Pharmacokinetic Models: Sensitivity to Uncertainty , 2007, Journal of biopharmaceutical statistics.

[22]  Alain Mallet,et al.  Optimal design in random-effects regression models , 1997 .

[23]  M. Avram,et al.  Dose‐Finding and Pharmacokinetic Study of Intramuscular Midazolam , 1987, Journal of clinical pharmacology.

[24]  George E. P. Box,et al.  SEQUENTIAL DESIGN OF EXPERIMENTS FOR NONLINEAR MODELS. , 1963 .

[25]  J. Schumacher,et al.  Chapter 27 – Anesthesia and Analgesia , 2006 .

[26]  Anthony C. Atkinson,et al.  DT-optimum designs for model discrimination and parameter estimation , 2008 .

[27]  Martijn P. F. Berger,et al.  OPTIMAL ALLOCATION OF TIME POINTS FOR THE RANDOM EFFECTS MODEL , 1999 .

[28]  S L Shafer,et al.  Comparative absorption kinetics of intramuscular midazolam and diazepam , 1996, Canadian journal of anaesthesia = Journal canadien d'anesthesie.

[29]  P. Doelken,et al.  Droperidol Causes a Dose‐dependent Prolongation of the QT Interval , 1994, Anesthesia and analgesia.

[30]  M. Krams,et al.  Innovative Approaches for Designing and Analyzing Adaptive Dose-Ranging Trials , 2007, Journal of biopharmaceutical statistics.

[31]  Peter B Chase,et al.  A retrospective review of the use and safety of droperidol in a large, high-risk, inner-city emergency department patient population. , 2002, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.

[32]  J. W. A. S. Sander,et al.  A comparative pharmacokinetic study of intravenous and intramuscular midazolam in patients with epilepsy , 1991, Epilepsy Research.

[33]  P. Laycock,et al.  Optimum Experimental Designs , 1995 .

[34]  Gordon Graham,et al.  A program for the optimum design of pharmacokinetic, pharmacodynamic, drug metabolism and drug-drug interaction models , 2005, Comput. Methods Programs Biomed..

[35]  France Mentré,et al.  Development and implementation of the population Fisher information matrix for the evaluation of population pharmacokinetic designs , 2001, Comput. Methods Programs Biomed..

[36]  A. Atkinson,et al.  The design of experiments for discriminating between two rival models , 1975 .

[37]  M. J. Box Simplified Experimental Design , 1971 .

[38]  John Eccleston,et al.  On optimal design for discrimination and estimation , 2004 .

[39]  Sergei Leonov,et al.  OPTIMAL POPULATION DESIGNS FOR PK MODELS WITH SERIAL SAMPLING , 2004, Journal of biopharmaceutical statistics.

[40]  H. Chernoff Locally Optimal Designs for Estimating Parameters , 1953 .

[41]  France Mentré,et al.  Design evaluation and optimisation in multiple response nonlinear mixed effect models: PFIM 3.0 , 2010, Comput. Methods Programs Biomed..

[42]  S B Duffull,et al.  Optimal Crossover Designs for Logistic Regression Models in Pharmacodynamics , 2006, Journal of biopharmaceutical statistics.

[43]  M Tod,et al.  Implementation of OSPOP, an algorithm for the estimation of optimal sampling times in pharmacokinetics by the ED, EID and API criteria. , 1996, Computer methods and programs in biomedicine.

[44]  D. Cox,et al.  Planning Experiments for Discriminating between Models , 1974 .

[45]  William A. Cressman,et al.  Absorption, metabolism and excretion of droperidol by human subjects following intramuscular and intravenous administration. , 1973, Anesthesiology.

[46]  W A Cressman,et al.  Absorption, metabolism and excretion of droperidol by human subjects following intramuscular and intravenous administration. , 1973, Anesthesiology.

[47]  Barbara Bogacka,et al.  D-efficient window experimental designs , 2008 .

[48]  H. Cramér Mathematical methods of statistics , 1947 .

[49]  Malcolm Rowland,et al.  Optimal Design for Multivariate Response Pharmacokinetic Models , 2006, Journal of Pharmacokinetics and Pharmacodynamics.

[50]  Jean-Marie Rocchisani,et al.  Comparison of ED, EID, and API Criteria for the Robust Optimization of Sampling Times in Pharmacokinetics , 1997, Journal of Pharmacokinetics and Biopharmaceutics.

[51]  L B Sheiner,et al.  Learning versus confirming in clinical drug development , 1997, Clinical pharmacology and therapeutics.

[52]  Anthony C. Atkinson,et al.  Optimum Experimental Designs , 1992 .

[53]  W. G. Hunter,et al.  Design of experiments for parameter estimation in multiresponse situations , 1966 .

[54]  F. Hsuan,et al.  Adaptive Designs for Dose-Finding Studies Based on Sigmoid E max Model , 2007, Journal of biopharmaceutical statistics.

[55]  Stephen B Duffull,et al.  Development of a sufficient design for estimation of fluconazole pharmacokinetics in people with HIV infection. , 2008, British journal of clinical pharmacology.

[56]  Donald Geman,et al.  Stochastic relaxation, Gibbs distributions, and the Bayesian restoration of images , 1984 .

[57]  M. Kirk,et al.  Droperidol, QT prolongation, and sudden death: what is the evidence? , 2003, Annals of emergency medicine.

[58]  N. Votolato,et al.  The use of intramuscular benzodiazepines and antipsychotic agents in the treatment of acute agitation or violence in the emergency department. , 2006, The Journal of emergency medicine.

[59]  J. Kiefer,et al.  The Equivalence of Two Extremum Problems , 1960, Canadian Journal of Mathematics.

[60]  P. Hartvig,et al.  Pharmacokinetics of midazolam in total i.v. anaesthesia. , 1987, British journal of anaesthesia.

[61]  Stephen B. Duffull,et al.  Prospective Evaluation of a D-Optimal Designed Population Pharmacokinetic Study , 2003, Journal of Pharmacokinetics and Pharmacodynamics.

[62]  Jon Wakefield,et al.  Bayesian individualization via sampling-based methods , 1996, Journal of Pharmacokinetics and Biopharmaceutics.

[63]  Stephen B Duffull,et al.  The time course of drug effects , 2009, Pharmaceutical statistics.

[64]  L. Endrenyi Design of Experiments for Estimating Enzyme and Pharmacokinetic Parameters , 1981 .

[65]  Andrew C. Hooker,et al.  Robust Population Pharmacokinetic Experiment Design , 2005, Journal of Pharmacokinetics and Pharmacodynamics.

[66]  Ian Whyte,et al.  Safety and effectiveness of high‐dose midazolam for severe behavioural disturbance in an emergency department with suspected psychostimulant‐affected patients , 2008, Emergency medicine Australasia : EMA.

[67]  J O'Quigley,et al.  Continual reassessment method: a practical design for phase 1 clinical trials in cancer. , 1990, Biometrics.

[68]  L C Ward,et al.  Optimal designs for studying bioimpedance , 2007, Physiological measurement.

[69]  Doug Sellman,et al.  Alcohol and drug treatment population profile: a comparison of 1998 and 2004 data in New Zealand. , 2006, The New Zealand medical journal.

[70]  Leon Aarons,et al.  Optimisation of sampling windows design for population pharmacokinetic experiments , 2008, Journal of Pharmacokinetics and Pharmacodynamics.

[71]  E. Walter,et al.  Robust experiment design via maximin optimization , 1988 .

[72]  Leon Aarons,et al.  Analytical Expressions for Combining Population Pharmacokinetic Parameters from Different Studies , 2008, Journal of biopharmaceutical statistics.

[73]  C. R. Rao,et al.  Information and the Accuracy Attainable in the Estimation of Statistical Parameters , 1992 .

[74]  Lewis B. Sheiner,et al.  Evaluation of methods for estimating population pharmacokinetic parameters II. Biexponential model and experimental pharmacokinetic data , 1981, Journal of Pharmacokinetics and Biopharmaceutics.

[75]  G. W. Morgan,et al.  Kinetic Data Analysis, Design and Analysis of Enzyme and Pharmacokinetic Experiments , 1981 .

[76]  G. Elfving Optimum Allocation in Linear Regression Theory , 1952 .

[77]  W. G. Hunter,et al.  The use of prior distributions in the design of experiments for parameter estimation in non-linear situations. , 1967, Biometrika.

[78]  John Battaglia,et al.  Pharmacological Management of Acute Agitation , 2012, Drugs.

[79]  L Pronzato,et al.  Optimal experiment design for nonlinear models subject to large prior uncertainties. , 1987, The American journal of physiology.

[80]  A. Wald On the Efficient Design of Statistical Investigations , 1943 .

[81]  W. G. Cochran Experiments for Nonlinear Functions (R.A. Fisher Memorial Lecture) , 1973 .

[82]  W. J. Studden,et al.  Theory Of Optimal Experiments , 1972 .

[83]  William L. Goffe,et al.  SIMANN: FORTRAN module to perform Global Optimization of Statistical Functions with Simulated Annealing , 1992 .

[84]  Leon Aarons,et al.  Optimum blood sampling time windows for parameter estimation in population pharmacokinetic experiments , 2006, Statistics in medicine.

[85]  Lewis B. Sheiner,et al.  Evaluation of methods for estimating population pharmacokinetic parameters. III. Monoexponential model: Routine clinical pharmacokinetic data , 1983, Journal of Pharmacokinetics and Biopharmaceutics.

[86]  Lewis B. Sheiner,et al.  Evaluation of methods for estimating population pharmacokinetic parameters. I. Michaelis-menten model: Routine clinical pharmacokinetic data , 1980, Journal of Pharmacokinetics and Biopharmaceutics.

[87]  D. Taylor,et al.  Randomized clinical trial comparing intravenous midazolam and droperidol for sedation of the acutely agitated patient in the emergency department. , 2006, Annals of emergency medicine.

[88]  M. Leider Goodman & Gilman's The Pharmacological Basis of Therapeutics , 1985 .

[89]  M. J. Eadie,et al.  The pharmacokinetics of midazolam in man , 2004, European Journal of Clinical Pharmacology.

[90]  Alan Maloney,et al.  An example of optimal phase II design for exposure response modelling , 2010, Journal of Pharmacokinetics and Pharmacodynamics.

[91]  John H Shale,et al.  A review of the safety and efficacy of droperidol for the rapid sedation of severely agitated and violent patients. , 2003, The Journal of clinical psychiatry.

[92]  France Mentré,et al.  Further Developments of the Fisher Information Matrix in Nonlinear Mixed Effects Models with Evaluation in Population Pharmacokinetics , 2003, Journal of biopharmaceutical statistics.

[93]  P. Zed,et al.  Drug-Related Visits to the Emergency Department , 2005 .

[94]  France Mentré,et al.  Design Optimization in Nonlinear Mixed Effects Models Using Cost Functions: Application to a Joint Model of Infliximab and Methotrexate Pharmacokinetics , 2009 .

[95]  David Z. D'Argenio,et al.  Optimal sampling times for pharmacokinetic experiments , 1981, Journal of Pharmacokinetics and Biopharmaceutics.

[96]  M. J. Box Some Experiences with a Nonlinear Experimental Design Criterion , 1970 .

[97]  M. J. Box The Occurrence of Replications in Optimal Designs of Experiments to Estimate Parameters in Non‐Linear Models , 1968 .

[98]  Mats O Karlsson,et al.  Optimal Adaptive Design in Clinical Drug Development: A Simulation Example , 2007, Journal of clinical pharmacology.

[99]  I. Patel,et al.  Effects of Age, Gender and Oral Contraceptives on Intramuscular Midazolam Pharmacokinetics , 1988, Journal of clinical pharmacology.

[100]  A. Atkinson,et al.  Optimal design : Experiments for discriminating between several models , 1975 .

[101]  D Z D'Argenio,et al.  Incorporating prior parameter uncertainty in the design of sampling schedules for pharmacokinetic parameter estimation experiments. , 1990, Mathematical biosciences.

[102]  Shane Darke,et al.  Non-fatal cocaine overdose among injecting and non-injecting cocaine users in Sydney, Australia. , 2004, Addiction.

[103]  J. Kiefer,et al.  Optimum Designs in Regression Problems , 1959 .

[104]  H. L. Lucas,et al.  DESIGN OF EXPERIMENTS IN NON-LINEAR SITUATIONS , 1959 .

[105]  W. G. Cochran Experiments for Nonlinear Functions , 1973 .

[106]  J. I The Design of Experiments , 1936, Nature.

[107]  Weng Kee Wong,et al.  On the Equivalence of Constrained and Compound Optimal Designs , 1994 .